Study of drug combo and radiation for advanced soft tissue sarcoma
Part of Cancer clinical trials.
This trial tests a combination of targeted therapy, chemotherapy, and radiation for advanced soft tissue sarcoma that has not responded to standard treatment. It aims to see if the combination can help patients live longer or shrink their tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 75 years old.
- You have advanced soft tissue sarcoma that has worsened after at least one prior treatment.
- You are in fairly good health, able to care for yourself and up and about (ECOG 0-1).
- Your blood counts, kidney, and liver function are within acceptable ranges.
- You are willing to use effective birth control during and for 3 months after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called HS-20093 combined with other treatments for people with advanced bone or soft tissue sarcoma. It aims to find safe and effective combinations for those who haven't responded to standard treatments.
This trial tests a new combination of radiation therapy and an immunotherapy approach (called PraG) for people with advanced soft tissue sarcoma that can't be removed by surgery or has spread. The goal is to see if this treatment can shrink tumors and improve outcomes.
This trial tests whether adding immunotherapy drugs (anlotinib and penpulimab) to radiation before surgery can help treat soft tissue sarcoma—a type of cancer in muscles, fat, or connective tissue. The goal is to shrink the tumor and improve surgical outcomes.
This trial tests a newer way of giving radiation (spatially fractionated) compared to standard radiation for people with large soft tissue sarcomas. It aims to see if the new method works better.
This trial tests two injectable medications (OVV-01 and AK112) combined together to treat advanced soft tissue sarcoma—a cancer that has spread or cannot be surgically removed—in patients whose previous treatments have failed. The goal is to see if injecting these drugs directly into tumors can help shrink them and improve outcomes.
This trial tests a combination of chemotherapy, radiation, and two newer drugs (anlotinib and bempegaldesleukin) for people with advanced soft tissue sarcoma that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Soft Tissue Sarcoma (STS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.